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ABSTRACT 
The prognostic value of volume status assessment by bioelectrical 
impedance analysis and lung ultrasound on mortality in septic acute 
kidney injury patients undergoing continuous renal replacement therapy 
 
Seung Gyu Han 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Tae-Hyun Yoo) 
 
Background Septic acute kidney injury (AKI) is one of the most common 
causes in critically ill patients requiring continuous renal replacement therapy 
(CRRT). The fluid status of the patient is known as a significant risk factor for 
mortality in those patients. Therefore, it is necessary to find an objective 
assessment of volume status. The aim of present study is to elucidate the impact 
of fluid status assessed by bioelectrical impedance analysis (BIA) and lung 
ultrasound on clinical outcomes in septic AKI patients with CRRT. 
Methods Septic AKI patients requiring CRRT between April 2014 and 
February 2015 at Yonsei University Health System were included. Surrogates 
of volume status were defined by 1) percent of body weight change between 
CRRT initiation and admission day, 2) over-hydration (OH)/extracellular water 
(ECW) measured by BIA, and 3) B-lines measured by lung ultrasound (US). 
Prognostic values of surrogates of volume status for 28-day mortality were 
evaluated. 
Results Among the 36 enrolled patients, 19 (52.8%) patients died during the 
follow-up duration. The mean percentage of weight change and OH/ECW 
measured by BIA was 5.3±20.7 % and 0.3±0.1 L/L. The median number of 
B-lines counted by lung US was 6 (interquartile range 4-10). Kaplan-Meier 
analysis showed that the risk for 28-day mortality was higher in patients with 
the highest OH/ECW tertile compared to patients with lower OH/ECW values 
(log-rank test, P=0.020). Percent of weight change and the number of B-lines 
were not significantly related with 28-day mortality risk (log-rank test, P=0.443 
 2 
and P=0.450 respectively). Multivariate Cox proportional hazard regression 
analysis showed that higher OH/ECW measured by BIA was an independent 
risk factor for 28-day mortality after adjustment of confounding factors 
(HR=3.83, 95% CI=1.04-14.03, P=0.043). 
Conclusion Higher OH/ECW measured by BIA was an independent risk factor 
for 28-day mortality in septic AKI patients undergoing CRRT. Determining 
fluid status by BIA could be a useful method to stratify mortality risk in this 
patient group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words: continuous renal replacement therapy, bioelectrical impedance 
analysis, lung ultrasound 
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I. INTRODUCTION 
Acute kidney injury (AKI) is one of the most common complications among 
critically ill patients, and occurs around up to 35% of this patient group. It was 
reported that one third of AKI is due to sepsis.1 Continuous renal replacement 
therapy (CRRT) is preferred as a treatment of septic AKI to eliminate toxic 
metabolite and overloaded fluid. According to previous study, CRRT was used 
in more than 80% of patients with severe kidney injury.2 In spite of many efforts 
to promote survival of this patient group, mortality rate of patients with septic 
AKI remains high.3  
 After Ronco et al. proposed that increased dose of ultrafiltration improved 
survival rate, several following studies were performed to evaluate the efficacy 
of CRRT dose modification on patient survival. But, it was recently reported by 
Bellomo et al. (RENAL trial) and Palevsky et al. (ATN trial) that increment of 
CRRT dose did not present any survival benefit.4 Therefore, novel approach to 
alleviate survival rate of these patient group is required. Meanwhile, fluid status 
of the patient with septic AKI was proved to be an independent factor for 
survival rate. Accordingly, it is predictable that control of patients’ fluid 
overload by way of CRRT be associated with improved survival rate.  
 One of the recently suggested methods to assess the patient’s fluid status is 
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bioelectrical impedance analysis (BIA), which can assess the fluid status of the 
patient as well as body composition by measuring the body’s electrical 
resistance varying with patient’s medical condition.5 BIA is already clinically 
used in patients undergoing intermittent hemodialysis to assess fluid status and 
modify dry weight, so that the patients’ long-term prognosis improves by 
optimizing blood pressure and cardiovascular parameters such as NT-pro BNP 
or pulse wave velocity. 6,7 Another novel method is lung ultrasound (US) which 
can estimate water content in the lung. The rationale of the technique is that 
under circumstance of pulmonary congestion, the US beam is reflected by 
thickened interlobular septa, a phenomenon generating hyper-echoic 
reverberation artifacts between edematous septa and the overlying pleura.8 
These vertical US artifacts appear as the so-called lung comets on the screen, 
which can be considered as B-lines. A recent study also demonstrated that, in 
patients undergoing intermittent hemodialysis, B-lines on the lung US can 
estimate volume status before and after hemodialysis.9  
 Previous studies revealed that critically ill patients suffer fluid overload either 
in need of CRRT or not, and the extent of fluid overload is associated with the 
patient’s prognosis. And the same is relevant in patients with septic AKI who 
require CRRT.10 Therefore, this study is to elucidate the association of 
assessment of fluid status by BIA and lung US in patients with septic AKI in 
need of CRRT to the patient’s prognosis. 
 
 
II. MATERIALS AND METHODS 
1. Patients and ethics 
A single center prospective observational study was conducted between April 
2014 and February 2015. I included totally 36 patients in the study who 
underwent CRRT and were 20 years or older and satisfy following three criteria, 
1) consensus criteria for sepsis, 2) AKI of Injury stage or severer stage in risk, 
injury, and failure; and loss and end-stage kidney disease (RIFLE) criteria. 3) 
AKI not explained other than sepsis. Sepsis is defined when patients have 
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evidence of infection and more than two of the following systemic 
inflammatory response syndrome (SIRS) criteria: body temperature >38 or 
<36 °C; heart rate >90/ min; hyperventilation evidenced by respiratory rate >20/ 
min or PaCO2 <32 mmHg; and white blood cell (WBC) count >12,000 cells/ 
㎕, <4,000/㎕ or band forms > 10%.11 Infection is confirmed when patients 
satisfy one of the following: WBCs in normally sterile fluid; perforated viscus, 
source of infection detected on radiologic exams.12 AKI is diagnosed and staged 
according to RIFLE criteria: Risk: urine output (UO)  < 0.5ml/kg/hr × 6 hour 
or serum creatinine (SCr) increased 1.5 to 2 times baseline; Injury: UO < 
0.5ml/kg/hr × 12 hour or SCr increased 2 to 3 times baseline; Failure: UO < 
0.3ml/kg/hr ×24 hour or SCr increased more than 3 times baseline; Loss of 
function: complete loss of kidney function > 4weeks (requiring dialysis).13 
Patient who satisfies one of the following is excluded: 1) patients younger than 
19 years or older than 80 years. 2) patients who have been undergoing 
hemodialysis due to end stage renal disease (ESRD) 3) patients who are in 
terminal stage malignancy. 4) patients with AKI from other causes than sepsis. 
5) patients with intra-cardiac devices (pacemaker, implantable cardioverter- 
defibrillator etc.) 6) patients with CRRT for non-renal indications. 7) patients 
with negative OH value in BIA measurement. During the study, all patients 
were treated by a conventional CRRT regimen.14 I classified the patients into 
survivor and non-survivor according to 28-day mortality. The hospital ethics 
committee approved the study and waived the need for informed consent 
because of the anonymous and observational fashion of the study. 
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Figure 1. Flow chart of the study population 
 
 
Enrollment criteria 
1. SIRS 
2. Culture proven infection, signs of 
infection 
3. AKI higher than Injury stage in RIFLE 
criteria 
4. AKI not explained by other than sepsis 
5. Agreed by the patient 
Exclusion criteria 
1. Age<19, age ≥ 80 
2. History of HD or KT 
3. Terminal stage malignancy 
4. AKI from other than sepsis 
5. Patients with intra-cardiac device such as 
Pacemaker, CRT or ICD 
6. CRRT for non-renal indications 
7. No volume overload in BIA 
Totally 36 patients enrolled 
Survivor (n=19) Non-survivor (n=17) 
Abbreviations: SIRS, systemic inflammatory response syndrome; AKI, acute kidney 
injury; HD, hemodialysis; KT, kidney transplantation; CRT, cardiac 
resynchronization therapy; ICD, implantable cardioverter-defibrillator, CRRT, 
continuous renal replacement therapy; BIA, bioelectrical impedance analysis 
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2. CRRT procedure 
The treatment initiation was decided by a nephrologist. Vascular access for 
CRRT was placed via internal jugular vein or femoral vein. CRRT was 
performed with Prismaflex® (Gambro, Stockholm, Sweden) in the ICU. 
Hemosol B0® (bicarbonate-buffered solution, Gambro) was used with a 
replacement fluid amounting 30-40 ml/kg/hr with a blood flow rate of 150-200 
ml/min. ST100® (Gambro) is used as a polysulfone membrane filter. Changes in 
maintenance of CRRT, blood flow rate, replacement fluid flow or ultrafiltration 
rate were made by the physician’s decision according to the patients’ clinical 
condition. CRRT is weaned when the patients satisfied on of the following: 1) 
systolic blood pressure is maintained >120 mmHg without use of inotropics and 
heart rate under 90 beats per minute. 2) UO > 1,000 ml/day with or without the 
use of diuretics. 3) conversion to conventional hemodialysis. 
3. Data collection 
Patient data were collected from the electronic medical record prospectively in 
Yonsei University Health System, Seoul, Korea. Demographic, clinical and 
biochemical data at the time of CRRT initiation were collected. In this study, I 
supposed three surrogates of volume status. Weight change (%) is defined as 
difference of body weight at CRRT initiation from body weight at the time of 
admission which is normalized by body weight at the time of admission. Body 
weight was measured by scale. Weight change (%) was obtained by following 
equation. 
 
 
The other two surrogates were measured by devices at the time of CRRT 
initiation. OH was measured by BIA, and the value was normalized by ECW 
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(OH/ECW, L/L) to be kept relative. B-lines were also measured by lung US at 
the time of CRRT initiation. Lung US was performed with a portable US 
scanner (GE Logiq Book XP® General Electric Health care, New York, USA) 
with a 2-3.6 MHz phased array cardiac assessment EM 3S-RS probe. The 
numbers of B-lines were measured from four points of the chest: the intercostal 
spaces between third and fourth ribs and sixth and seventh ribs on each 
mid-clavicular line. The numbers were recorded at each point and summed up 
as the number of B-lines. At the same time, BIA is performed with Body 
Composition Monitor-BCM® (Fresinius Medical Care, Bad Homburg, 
Germany). Two each electrodes on ipsilateral arm and leg were attached for the 
measurement. Using body fluid model, BIA measures electric resistance of the 
body to assess the composition of the patient’s body. Body weight is composed 
of Lean tissue mass (LTM), Adipose tissue mass (ATM) and over-hydration 
(OH). In LTM and ATM, extracellular water (ECW) and intracellular water 
(ICW) exist at constant ratio, however, OH is assumed to be composed of solely 
ECW in the body fluid model, thus OH can be calculated by subtracting the 
average human’s ECW of the same height and body weight at one’s normal 
health condition from ECW of the patients. Acute Physiology and Chronic 
Health Evaluation (APACHE) II score was determined at the time of ICU 
admission. Estimated glomerular filtration rate (eGFR) was also calculated 
using the simplified Modification of Diet in Renal Disease equation.  
 
4. Statistical analysis 
Statistical analysis was performed by SPSS for Windows®, version 18.0 
(SPSS, Inc, Chicago, IL, USA). Values are presented as mean ± SD for 
continuous variables, and as numbers and percentages for categorical variables. 
Baseline characteristics of the groups were compared using the Student t test or 
ANOVA for continuous and χ2 test for categorical variables. In the present 
study, I evaluated 28-day mortality as a primary end point. 
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Comparison of parameters of BIA and lung US between two groups was made 
using student T-test. The impact of variables on 28-day mortality in septic AKI 
patients was determined using Cox proportional hazard model analysis, and the 
results were presented as hazard ratios (HRs) and 95% confidence intervals 
(CIs).  
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III. RESULTS 
1. Baseline characteristics 
The baseline patient characteristics are shown in table 1. A total of 36 patients 
were included from April 2014 to February 2015. The mean age was 64.4±14.6 
years, and 22 patients (61.1%) were male. The most common comorbidity is 
hypertension (18, 50.1%) followed by diabetes mellitus (14, 38.9%) and 
malignancy (12, 33.3%). At the time of CRRT initiation, the mean SCr level was 
2.9±1.7 mg/dL. During the study period, 19 patients (52.8%) died. Heart rate, 
systolic blood pressure (SPB), diastolic blood pressure (DPB) and mean arterial 
pressure (MAP) did not differ significantly in both groups. Body weight on 
admission and CRRT initiation showed no difference between two groups.  
However, weight change (%) did not show significant difference in survivor 
group and non-survivor group (5.7±21.7 vs. 4.9±20.0, P=0.913). The ratio of 
anuric patients whose UO was less than 100ml/day and UO at the time of 
CRRT initiation showed no difference, however, survivor group showed higher 
SCr (3.7±2.0 vs. 2.0±0.7, P=0.002) compared with non-survivor group. Other 
laboratory values did not differ statistically significant, but lactate (3.3±4.3 vs. 
9.3±7.2, P=0.007) level was significantly lower in survivor group. APACHE 
Ⅱ score was significantly lower in survivor group (21.5±5.4 vs. 26.9±6.7, 
P=0.011). 
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Table 1. Baseline characteristics of patients with septic AKI on CRRT 
 Total Survivor Non-survivor p-value 
No. of patients, n (%) 36 (100) 19 (52.8) 17 (47.2)  
Age at CRRT (yr) 64.6 ± 14.6 65.3 ± 13.1 63.4 ± 16.4 0.702 
Male sex, n (%) 22 (61.1) 12 (63.2) 10 (58.8) 0.790 
Vital sign     
 SBP (mmHg) 131.4 ± 23.6 136.8 ± 24.6 125.4 ± 21.4 0.149 
 DBP (mmHg) 65.9 ± 13.5 67.6 ± 15.4 64.0 ± 11.2 0.790 
 MAP (mmHg) 87.7 ± 15.1 90.7 ± 16.3 84.5 ± 13.3 0.223 
 Heart rate (beats per minute) 101.4 ± 22.7 94.6 ± 19.1 109.0 ± 24.6 0.057 
 Body temperature (°C) 36.8 ± 0.9 36.8 ± 0.7 36.8 ± 1.0 0.991 
 Respiratory rate (per minute) 20.5 ± 4.3 19.3 ± 3.6 21.9 ± 4.7 0.073 
Body weight     
 Body weight on admission (kg) 59.5 ± 8.7 57.8 ± 8.9 61.4 ± 8.2 0.213 
 Body weight on CRRT initiation (kg) 61.6 ± 9.3 59.9 ± 8.6 63.6 ± 9.8 0.239 
 Weight change (%) 5.3 ± 20.6 5.7 ± 21.7 4.9 ± 20.0 0.913 
Urine output at CRRT initiation     
 Anuria, n (less than 100ml/day, %) 17 8 (42.1) 9 (52.9) 0.516* 
 Average urine output (ml) 738.6 ± 1351.6 1017.9 ± 1545.2 426.5 ± 1055.5 0.194 
Medical history     
 CKD, n (%) 5 (13.9) 4 (21.1) 1 (5.9) 0.206* 
 DM, n (%) 14 (38.9) 9 (47.4) 5 (29.4) 0.270** 
 COPD, n (%) 4 (11.1) 3 (15.8) 1 (5.9) 0.345* 
 Liver disease, n (%) 4 (11.1) 1 (5.3) 3 (17.6) 0.260* 
HTN, n (%) 18 (50.0) 10 (52.6) 8 (47.1) 0.500** 
CAOD, n (%) 6 (16.7) 3 (15.8) 3 (17.6) 0.614* 
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Initial Lab     
 WBC (×103/㎕) 15.0 ± 10.0 15.7 ± 9.6 14.1 ± 10.7 0.644 
 Hemoglobin (mg/dL) 10.1 ± 1.7 10.4 ± 1.4 9.8 ± 2.0 0.294 
 Platelet count (×103/㎕) 136.0 ± 139.6 144.2 ± 142.8 126.8 ± 139.8 0.716 
BUN (mg/dL) 49.3 ± 25.6 51.7 ± 25.6 46.6 ± 26.1 0.556 
SCr (mg/dL) 2.9 ± 1.7 3.7 ± 2.0 2.0 ± 0.7 0.002 
Sodium (mmol/L) 139.5 ± 4.9 138.9 ± 3.9 140.1 ± 5.9 0.505 
Potassium (mmol/L) 4.3 ± 0.8 4.3 ± 0.6 4.3 ± 0.9 0.902 
Total CO2 (mmol/L) 19.2 ± 5.9 20.6 ± 4.7 17.7 ± 6.9 0.149 
Calcium (mg/dL) 8.4 ± 1.1 8.5 ± 0.9 8.4 ± 1.3 0.676 
Phosphate (mg/dL) 4.5 ± 1.9 4.5 ± 1.7 4.4 ± 2.1 0.832 
Albumin (g/dL) 2.7 ± 0.6 2.8 ± 0.4 2.6 ± 0.7 0.276 
High sensitive-CRP (mg/dL, IQR) 101.5 (40.1-175.5) 81.4 (36.9-139.3) 136.0 (26.4-244.5) 0.149 
Lactate (mmol/L) 6.0 ± 6.4 3.4 ± 4.3 9.3 ± 7.2 0.007 
APACHE Ⅱ 24.1 ± 6.5 21.5 ± 5.4 26.9 ± 6.7 0.011 
* Fisher’s exact test 
** χ2 test 
Abbreviations: CRRT, continuous renal replacement therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
MAP, mean arterial pressure; CKD, chronic kidney disease; DM, diabetes mellitus; COPD, chronic obstructive pulmonary 
disease; HTN, hypertension; CAOD, coronary artery obstructive disease; WBC, white blood cell; BUN, blood urea 
nitrogen; SCr, serum creatinine concentration; CRP, C-reactive protein; IQR, interquartile range; APACHE Ⅱ, Acute 
Physiology and Chronic Health Evaluation Ⅱ 
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2. Surrogates of volume status 
Values of three surrogates at the time of CRRT initiation are shown in last 
three rows from the bottom of Table 2 and other several values measured by 
BIA are also shown.  
Table 2. Surrogates of volume status at CRRT initiation 
 Survivor (n=19) Non-survivor (n=17) p-value 
OH (L) 5.4 ± 4.3 6.9 ± 3.8 0.275 
VUrea (L) 38.5 ± 15.3 36.9 ± 17.4 0.816 
ECW (L) 30.5 ± 29.3 24.7 ± 8.8 0.437 
ICW (L) 26.7 ± 14.0 26.4 ± 15.3 0.938 
Weight change (%) 5.7 ± 21.7 4.9 ± 20.0 0.913 
OH/ECW (L/L) 0.21 ± 0.14 0.28 ± 0.13 0.110 
B-lines on lung US 6.7 ± 3.7 7.0 ± 4.6 0.821 
 
 
There was a tendency that survivors showed lower OH/ECW value (0.21±0.14 
vs. 0.28±0.13, P=0.110) in BIA and the number of B-lines (6.7±3.7 vs. 7.0±4.6, 
P=0.821) in Lung US. However, there was no significant difference in volume 
status parameters of BIA and lung US between survivor group and non-survivor 
group. 
 
 
 
 
 
 
Abbreviations: OH, over-hydration; VUrea, volume of distribution of urea; 
ECW, extra-cellular water; ICW intra-cellular water; E/I ratio, ECW/ICW 
ratio; lung US, lung ultrasound 
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3. Correlations among three surrogates 
As shown in Figure 2, three surrogates did not show significant correlations 
between each other, although each surrogate was supposed to be comparable to 
body status.  
 
 
Figure 2. Correlations among used assessment tools 
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4. Outcomes 
I classified the patients into three groups according to tertiles of each 
surrogates in order to evaluate primary outcome. Patient characteristics 
according to each surrogate are shown in Table 3, Table 4, and Table 5. Patient 
characteristics include demographic variables, echocardiographic variables that 
represent the patient’s cardiac function, and laboratory variables that are 
associated with severity of the patient’s status. Patient characteristics according 
to weight change tertiles did not show any significant difference among three 
tertiles except total CO2 (P=0.035), which was highest in tertile 2. However, 
there was no significant difference among tertiles when patients were divided 
according to OH/ECW by BIA and B-lines by lung US. 
I analyzed 28-day mortality according to each surrogate by comparing 
mortality rate of highest tertile versus lower two third tertiles. Kaplan-Meier 
plots revealed that 28-day mortality according to weight change and B-lines by 
lung US showed trends that survival rate of highest tertile was lower than that 
of lower two thirds (log-rank test, P=0.443 and P=0.450 respectively, Figure 4 A 
and C). However, 28-day survival rate of highest OH/ECW tertile showed 
significantly lower than that of lower two thirds as shown in figure 4 (log-rank 
test, P=0.020, Figure 4 B).  
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Table 3. Patient characteristics according to weight change tertiles 
 
Variables Weight change Tertile 1 
-14.8% (-21.5, -7.8) 
(n=12) 
Weight change Tertile 2 
0.2% (-3.8, 5.1) 
(n=12) 
Weight change Tertile 3 
28.6% (6.1, 55.4) 
(n=12) 
p-value 
Age (year) 62.6 ± 19.1 63.9 ± 14.8 66.3 ± 9.4 0.986 
Sex (male, %) 4 (33.3) 9 (75.0) 9 (75.0) 0.124 
BMI (kg/m2) 21.9 ± 2.1 22.4 ± 2.7 24.6 ± 3.0 0.044 
DM (%) 7 (58.3) 3 (15.7) 4 (33.3) 0.113 
CKD (%) 1 (8.3) 2 (16.7) 3 (15.7) 0.855 
Heart rate (BPM) 115.0 ± 25.6 95.3 ± 18.3 95.6 ± 20.6 0.060 
LVEDD (mm) 44.5 ± 6.7 48.2 ± 5.4 45.9 ± 9.3 0.100 
LAVI (mL/m2) 24.7 ± 8.6 30.9 ± 7.7 42.2 ± 24.6 0.231 
SCr (mg/dL) 2.4 ± 1.3 3.0 ± 2.1 3.3 ± 1.7 0.288 
Albumin (g/dL) 2.7 ± 0.4 2.8 ± 0.5 2.6 ± 0.7 0.295 
Total CO2 (mmol/L) 16.7 ± 7.6 22.3 ± 4.8 18.1 ± 4.1 0.035 
Lactate (mmol/L) 8.7 ± 7.3 3.8 ± 4.4 5.8 ± 7.1 0.500 
APACHEⅡ 23.7 ± 6.4 22.5 ± 4.5 26.2 ± 8.3 0.441 
 
Abbreviations: BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; BPM, beat per minute; 
LVEDD, left ventricular end diastolic diameter; LAVI, left atrial volume index; SCr, serum creatinine concentration; 
APACHE Ⅱ, Acute Physiology and Chronic Health Evaluation Ⅱ 
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Table 4. Patient characteristics according to OH/ECW tertiles by BIA 
 
Variables OH/ECW Tertile 1 
0.07 L/L (0.01, 0.17) 
(n=12) 
OH/ECW Tertile 2 
0.27 L/L (0.18, 0.32) 
(n=12) 
OH/ECW Tertile 3 
0.40.L/L (0.32, 0.45) 
(n=12) 
p-value 
Age (year) 62.4 ± 15.2 70.1 ± 8.8 60.3 ± 17.2 0.286 
Sex (male, %) 8 (22.2) 6 (16.7) 8 (22.2) 0.627 
BMI (kg/m2) 22.2 ± 3.4 23.4 ± 2.1 23.3 ± 2.9 0.530 
DM (%) 4 (11.1) 5 (13.9) 5 (13.9) 0.890 
CKD (%) 3 (8.3) 1 (2.8) 1 (2.8) 0.395 
Heart rate (BPM) 100.0 ± 17.5 95.3 ± 23.0 109.0 ± 26.6 0.257 
LVEDD (mm) 48.0 ± 5.7 44.8 ± 3.9 46.1 ± 10.6 0.335 
LAVI (mL/m2) 27.6 ± 8.2 32.2 ± 17.7 38.5 ± 21.4 0.511 
SCr (mg/dL) 3.6 ± 2.2 2.7 ± 1.8 2.4 ± 0.9 0.564 
Albumin (g/dL) 2.8 ± 0.4 2.8 ± 0.6 2.5 ± 0.6 0.105 
Total CO2 (mmol/L) 22.1 ± 3.7 17.3 ± 7.1 18.3 ± 5.8 0.114 
Lactate (mmol/L) 3.4 ± 4.2 7.4 ± 7.6 7.2 ± 6.6 0.561 
APACHEⅡ 21.6 ± 4.4 24.9 ± 7.7 25.8 ± 6.9 0.290 
 
 Abbreviations: BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; BPM, beat per minute; 
LVEDD, left ventricular end diastolic diameter; LAVI, left atrial volume index; SCr, serum creatinine concentration; 
APACHE Ⅱ, Acute Physiology and Chronic Health Evaluation Ⅱ 
 18 
Table 5. Patient characteristics according to B-lines tertiles by lung US 
 
Variables B-lines Tertile 1 
4 (0, 5) 
(n=12) 
B-lines Tertile 2 
7.5 (5, 8) 
(n=12) 
 B-lines Tertile 3 
12 (8, 15) 
(n=12) 
p-value 
Age (year) 64.6 ± 16.7 66.8 ± 11.4 61.5 ± 15.6 0.609 
Sex (male, %) 8 (66.7) 6 (50.0) 8 (66.7) 0.627 
BMI (kg/m2) 22.9 ± 3.2 22.9 ± 2.0 23.2 ± 2.9 0.950 
DM (%) 3 (25.0) 4 (33.3) 7 (58.3) 0.219 
CKD (%) 1 (8.3) 1 (8.3) 3 (25.0) 0.395 
Heart rate (BPM) 108.7 ± 27.7 94.2 ± 21.8 101.4 ± 16.8 0.345 
LVEDD (mm) 47.1 ± 7.1 46.8 ± 8.7 45.0 ± 6.2 0.857 
LAVI (mL/m2) 28.3 ± 9.5 34.6 ± 21.8 35.4 ± 17.5 0.696 
SCr (mg/dL) 3.3 ± 2.0 2.8 ± 1.9 2.6 ± 1.3 0.689 
Albumin (g/dL) 2.9 ± 0.6 2.8 ± 0.5 2.5 ± 0.4 0.246 
Total CO2 (mmol/L) 20.8 ± 6.2 18.4 ± 6.9 18.4 ± 4.6 0.309 
Lactate (mmol/L) 7.2 ± 6.9 5.9 ± 7.7 5.0 ± 4.8 0.340 
APACHEⅡ 20.1 ± 4.9 25.4 ± 7.1 26.0 ± 6.7 0.104 
 
 
 
 
Abbreviations: BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; BPM, beat per minute; 
LVEDD, left ventricular end diastolic diameter; LAVI, left atrial volume index; SCr, serum creatinine concentration; 
APACHE Ⅱ, Acute Physiology and Chronic Health Evaluation Ⅱ 
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Figure 3. Kaplan-Meier analysis of 28-day mortality according to A) weight change, B) OH/ECW by BIA, and C) 
B-lines by lung US 
A
 
B
 
C
 
 20 
Univariate cox proportional hazard model was performed. Variables which 
affected 28-day mortality other than OH/ECW (HR 2.929, CI 1.110-7.727, 
P=0.030) were total CO2 level (HR 0.922, CI 0.858-0.991, P=0.027), lactate 
level (HR 1.138, CI 1.051-1.232, P=0.001), and APACHE Ⅱ score (HR 1.126, 
CI 1.031-1.230, P=0.008). Traditional risk factors such as Lactate level and 
APACHE Ⅱ score that indicates severity of critically ill patients also predicted 
28-mortality in this patient group. 
Table 6. Univariate Cox proportional hazard model for 28-day mortality 
 
 HR (95%CI) p-value 
Weight change T3 (vs. T1+2) 1.461 (0.539-3.960) 0.456 
OH/ECW T3 (vs. T1+2) 2.929 (1.110-7.727)  0.030 
B-line T3 (vs. T1+2) 1.453 (0.536-3.937) 0.463 
Age (year) 0.995 (0.964-1.027) 0.778 
Female (vs. male) 1.033 (0.393-2.717) 0.947 
DM (vs. non-DM) 0.596 (0.210-1.694) 0.331 
CKD (vs. non-CKD) 0.268 (0.035-2.026) 0.202 
LVEDD (mm) 1.044 (0.972-1.121) 0.237 
LAVI (per ml/m2) 1.022 (0.997-1.048) 0.089 
Urine output/body weight (per cc/kg) 0.982 (0.951-1.013) 0.252 
tCO2 (per mmol/L) 0.922 (0.858-0.991) 0.027 
Lactate (per mmol/L) 1.138 (1.051-1.232) 0.001 
APACHEⅡ 1.126 (1.031-1.230) 0.008 
 
 
 
 
 
  
Abbreviations: T3, highest tertile; T1+2, lower two-thrids tertiles; HR, hazard 
ratio; CI, confidence interval; OH, over-hydration; ECW, extra-cellular water; 
DM, diabetes mellitus; CKD, chronic kidney disease; LVEDD, left ventricular 
end diastolic diameter; LAVI, left atrial volume index; APACHE Ⅱ, Acute 
Physiology and Chronic Health Evaluation Ⅱ 
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Table 7. Multivariate Cox proportional hazard models for 28-day mortality according to OH/ECW tertiles. 
 
Variables Model 1 Model 2 Model 3 
HR 
(95% CI) P-value 
HR 
(95% CI) P-value 
HR 
(95% CI) P-value 
OH/ECW T3 
(vs. T1+2) 
2.929 
(1.110-7.727) 0.030 
4.924 
(1.408-17.22) 0.013 
3.826 
(1.043-14.03) 0.043 
Age (per year)   1.019 (0.981-1.058) 0.331 
1.023 
(0.981-1.066) 0.289 
Female (vs. male)   0.877 (0.326-2.355) 0.794 
1.094 
(0.379-3.156) 0.868 
DM (vs. non-DM)   0.323 (0.082-1.271) 0.106 
0.314 
(0.088-1.120) 0.074 
CKD (vs. non-CKD)   0.319 (0.041-2.477) 0.274 
0.219 
(0.025-1.905) 0.169 
APACHE Ⅱ     0.079 (0.989-1.213) 0.079 
tCO2 (per mmol/L)     0.946 (0.861-1.039) 0.247 
 
 Abbreviations: HR, hazard ratio; CI, confidence interval; OH, over-hydration; ECW, extra-cellular water; DM, diabetes 
mellitus; CKD, chronic kidney disease; APACHE Ⅱ, Acute Physiology and Chronic Health Evaluation Ⅱ 
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Multivariate Cox proportional hazard model analyses were conducted. 
Analyses were performed according to each surrogate. Model 1 was crude 
model. Model 2 included demographic factors such as age, sex, DM and CKD 
history. Finally, model 3 included total CO2 level and APACHE Ⅱ score as 
shown in Table 7. OH/ECW predicted significant increase of 28-day mortality 
after adjustment of confounding factors (HR 3.826, CI 1.043-14.03, P=0.043). 
 
 
IV. DISCUSSION 
 This study was performed to investigate the prognostic value of changes in 
weight as a volume parameter and volume status assessment by BIA and lung 
US on mortality in septic AKI patients undergoing CRRT. In present study, 
three surrogates were used to measure volume status of the septic AKI patients 
undergoing CRRT. These surrogates were under investigation to verify their 
effectiveness in various circumstances. Previous studies revealed that fluid 
overload is associated with mortality of patients with septic AKI as well as 
treated with chronic dialysis.15 Several studies were performed on predictive use 
of BIA on chronic kidney disease on hemodialysis. Some of those studies 
revealed that values measured by BIA are associated with biochemical and 
parameters of hemodialysis such as dry weight and ultrafiltration volume.16 
Other recent study showed that fluid assessment and adjustment of dry weight 
by BIA improves clinical outcomes and all-cause mortality in patients 
undergoing conventional hemodialysis and peritoneal dialysis.17 However, 
usage of BIA in critically ill patients such as patients with septic shock is yet to 
be explored. Although numerous previous studies on critically ill patients 
emphasized of volume control, assessment tool for volume status is still elusive. 
An observational study performed on 37 patients with septic shock treated with 
CRRT showed that net balanced ultrafiltration reduced intra-abdominal pressure, 
total body water, ECW, and ICW in this patient group.18 In present study, a 
positive trend that increasing weight change and B-lines measured by lung US 
were associated with increasing risk of 28-day mortality, despite of lack of 
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statistical power. However, OH/ECW measured by BIA showed significant 
prognostic power on 28-day mortality in this patient group (HR=2.929, 
CI=1.110-7.727, P=0.030). In the future, large scale randomized control study 
on volume control using BIA is required for verification of effectiveness of BIA 
in this patient group for prediction of overall mortality. 
 As for the number of B-lines in lung US, it did not predict 28-day mortality 
with statistical significance in present study group. Since lung US was 
introduced, there have been many efforts to assess volume status in various 
patient groups. Though a few studies were performed on lung US for volume 
assessment, they dealt mainly with patients with chronic kidney disease 
undergoing intermittent hemodialysis. However, those studies verified 
usefulness of lung US only for prediction of pulmonary congestion and fail to 
verify predictive power of hemodynamic congestions such as pulmonary artery 
occlusion pressure.19 Potential use of lung US in the management of acute 
circulatory failure such as septic AKI seems yet to be examined.20 This study 
did not verify that the number of B-lines affect 28-day mortality. Meanwhile, 
other recent study also concluded the impact of integrated cardiopulmonary 
sonography including lung US on prognoses requires further study.21 That is, 
the role of lung US in critically ill patients such as patients with septic AKI is 
not clearly identified. 
Previous studies on the similar patient groups who were chronic hemodialysis 
patients showed conflicting results. One study of Basso et al. on reproducibility 
of BIA and lung US concluded correlation between BIA and lung US was 
statistically significant,22 while other study of Donadio et al. showed correlation 
between these two techniques was not significantly associated.23 In this study, 
lack of significant correlation of these two techniques may be because of 
relatively small sample size and non-homogeneous characteristics of the 
patients. In addition, B-lines in lung US can be detected when pulmonary 
edema or effusion arise from other etiologies than volume overload. Lung 
congestion due to different etiologies such as cardiac failure or liver failure, 
pneumonia, post-operative status could commonly result in increased number of 
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B-lines in lung US.  
The device that we used in this study calculates and displays OH in 
comparison with the healthy individuals with same height and body weight by 
using equations which was suggested by Moissl et al.24 This OH value required 
to be normalized by ECW to enhance accuracy of OH because OH values are 
dependent on physiological hydration properties of body tissues.25 Especially, 
previous study reported discrepancy among OH/ECW, OH/BMI and OH/body 
weight and accuracy of OH/ECW over OH/BMI or OH/body weight.26 So, I 
also chose OH/ECW as a surrogate of volume status in this study. 
In this study, there are several potential limitations that should be noted. First 
the study was performed small number of patients with heterogeneous 
characteristics. I did not take into consideration of various etiologies that 
generated B-lines in lung US, that is, B-lines could have been observed without 
obvious volume overload. In addition, it should be determined whether one 
performs measurement right before or long enough after administration of 
CRRT because administration of CRRT could be urgent to some patients with 
unstable vital sign. 
Finally, BIA values are known to be affected by numerous variables including 
body position, hydration status, consumption of food and beverages, ambient air 
and skin temperature, recent physical activity, and conductance of examining 
table.27 However, because this study involved critically ill patients and so many 
life-supporting devices were attached to the patients, the standardization of 
measurement condition was difficult. Minimization of interruption in BIA and 
Lung US measurement should be taken regarded in future studies.  
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V. CONCLUSION 
Higher OH/ECW measured by BIA was an independent risk factor for 28-day 
mortality in septic AKI patients undergoing CRRT. Determining fluid status by 
BIA could be a useful method to stratify mortality risk in this patient group. 
The large number of patients and prospective randomized control study 
should be needed to figure out the usefulness of a novel assessment for 
fluid status objectively. 
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ABSTRACT(IN KOREAN) 
CRRT를 필요로 하는 패혈성 급성 신손상 환자에서 
생체전기임피던스와 폐초음파를 이용한 체액상태의 평가가 
가지는 예후평가적 가치 
 
<지도교수 유태현> 
 
연세대학교 대학원 의학과 
 
한 승 규 
 
배경 패혈성 급성 신손상은 중환자실 치료를 필요로 하는 환자에서 
일어나는 가장 흔한 합병증 중 하나이다. CRRT 치료를 요하는 
환자에서 전신의 수분 상태는 환자의 예후를 평가하는데 있어 유의한 
위험요소로 밝혀져 있다. 이 연구에서는 CRRT를 필요로 하는 패혈성 
급성 신손상 환자에서 생체전기임피던스와 폐초음파를 이용한 
체액상태의 평가가 가지는 예후평가적 가치를 분석하였다. 
방법 2014년 4월부터 2015년 2월 사이에 본원에서 CRRT를 필요로 
하는 패혈성 급성 신손상 환자 36명을 대상으로 하여 전향적 
관찰연구를 시행하였다. 생체전기임피던스와 폐초음파는 CRRT의 
시작 시점에 시행하였다. 수분 상태를 평가하는 표지자로는 1) 
입원일과 CRRT 시작일의 체중변화, 2) 생체전기임피던스로 측정한 
over-hydration(OH)/extracellular water(ECW), 3) 폐 초음파로 측정한 
B-line의 수를 사용하였다. 1차 종점은 28일 생존률로 설정하였다. 
결과 36명 대상 환자 중, 연구 기간 동안 19(48.7%) 명의 환자가 
사망했다. 평균 체중변화와 생체전기임피던스로 측정된 OH/ECW 는 
각각 5.3±20.7 % 와 0.3±0.1 L/L 였다. 폐초음파로 측정한 B-line 개수의 
중앙값은 6 (사분위수범위 4-10)이었다. Kaplan-Meier 분석을 
시행하였을 때, 상위 삼분위의 OH/ECW 를 보이는 환자들이 나머지 
환자들에비해 28일 생존률이 유의하게 더 낮은 것으로 
나타났다(log-rank test, P=0.020). 체중변화와 B-line의 수는 28일 
생존률과 유의한 상관관계를 보이지는 않았다 (각각 log-rank test, 
P=0.443 and P=0.450). 다변량 Cox proportional hazard model analysis 를 
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시행한 결과 상위 삼분위수의 OH/ECW 는 혼란변수를 보정하고 난 
뒤에도 독립적인 위험요소인 것으로 밝혀졌다 (HR=3.83, 95% 
CI=1.04-14.03, P=0.043).  
결론 생체전기임피던스로 측정한 OH/ECW 값이 높은 것은 CRRT를 
필요로 하는 패혈성 급성 신손상 환자에서 독립적인 위험요소인 
것으로 밝혀졌다. 본 연구에서는 생체전기임피던스로 측정한 체내 
수분상태를 평가하는 것이 이 환자군의 생존률을 결정하는데 있어 
유용한 방법이 될 수 있다는 결과를 얻을 수 있었다. 이 연구는 이들 
새로운 측정방법을 활용하여 CRRT로 환자의 수분상태를 조절하는 
대규모의 무작위 제어 연구를 시행하는 데 대한 근거를 마련해 주고 
있다. 
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